Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational…
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust mKRAS-specific T cell responses…